Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) EVP Anne-Marie Duliege sold 16,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $3.51, for a total transaction of $57,915.00. Following the sale, the executive vice president now owns 16,500 shares in the company, valued at $57,915. The sale was disclosed in a filing with the SEC, which is available at this link.

Anne-Marie Duliege also recently made the following trade(s):

  • On Monday, July 2nd, Anne-Marie Duliege sold 5,000 shares of Rigel Pharmaceuticals stock. The shares were sold at an average price of $2.79, for a total transaction of $13,950.00.

Shares of RIGL stock remained flat at $$3.20 during trading on Friday. 1,438,839 shares of the company were exchanged, compared to its average volume of 2,490,401. Rigel Pharmaceuticals, Inc. has a 12 month low of $2.28 and a 12 month high of $4.71. The stock has a market cap of $532.62 million, a PE ratio of -5.16 and a beta of 1.10.

Rigel Pharmaceuticals (NASDAQ:RIGL) last posted its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.16). The firm had revenue of $1.79 million during the quarter, compared to analysts’ expectations of $0.30 million. equities research analysts forecast that Rigel Pharmaceuticals, Inc. will post -0.65 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC lifted its stake in Rigel Pharmaceuticals by 11.1% in the 2nd quarter. FMR LLC now owns 24,537,044 shares of the biotechnology company’s stock worth $69,440,000 after purchasing an additional 2,448,925 shares in the last quarter. BlackRock Inc. lifted its stake in Rigel Pharmaceuticals by 20.9% in the 2nd quarter. BlackRock Inc. now owns 13,392,367 shares of the biotechnology company’s stock worth $37,901,000 after purchasing an additional 2,312,498 shares in the last quarter. Palo Alto Investors LP lifted its stake in Rigel Pharmaceuticals by 0.8% in the 1st quarter. Palo Alto Investors LP now owns 3,966,087 shares of the biotechnology company’s stock worth $14,040,000 after purchasing an additional 30,503 shares in the last quarter. Rock Springs Capital Management LP lifted its stake in Rigel Pharmaceuticals by 4.0% in the 1st quarter. Rock Springs Capital Management LP now owns 2,575,000 shares of the biotechnology company’s stock worth $9,116,000 after purchasing an additional 100,000 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Rigel Pharmaceuticals by 47.7% in the 1st quarter. JPMorgan Chase & Co. now owns 2,021,618 shares of the biotechnology company’s stock worth $7,157,000 after purchasing an additional 652,856 shares in the last quarter. Institutional investors and hedge funds own 94.24% of the company’s stock.

RIGL has been the topic of a number of recent research reports. JPMorgan Chase & Co. restated an “overweight” rating and set a $7.00 price target on shares of Rigel Pharmaceuticals in a research note on Tuesday. BidaskClub cut shares of Rigel Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, June 21st. Zacks Investment Research upgraded shares of Rigel Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 price target on the stock in a research note on Wednesday, July 4th. ValuEngine upgraded shares of Rigel Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 28th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Rigel Pharmaceuticals in a research note on Thursday, August 9th. Two analysts have rated the stock with a sell rating and eight have assigned a buy rating to the stock. Rigel Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $7.59.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and immunoglobulin a nephropathy.

Read More: Return on Investment (ROI)

Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.